a2 Milk Posts Strong 1H26 Growth and Lifts FY26 Guidance
The a2 Milk Company (ASX: A2M) delivered a strong first half for FY26, with revenue rising 18.8% to NZ$993.5 million and EBITDA increasing 18.4% to NZ$155.0 million. NPAT from continuing operations grew 9.4% to NZ$112.1 million, supported by disciplined cost control and a 90.8% cash conversion rate. Performance was driven by double-digit Infant Milk Formula growth, accelerating Other Nutritionals, and resilient liquid milk sales across ANZ and the US. Management upgraded FY26 guidance, targeting mid-double-digit revenue growth and EBITDA margins of approximately 15.5%–16.0%.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
a2 Milk Posts Strong 1H26 Growth and Lifts FY26 Guidance
The a2 Milk Company (ASX: A2M) delivered a strong first half for FY26, with revenue rising 18.8% to NZ$993.5 million and EBITDA increasing 18.4% to NZ$155.0 million. NPAT from continuing operations grew 9.4% to NZ$112.1 million, supported by disciplined cost control and a 90.8% cash conversion rate. Performance was driven by double-digit Infant Milk Formula growth, accelerating Other Nutritionals, and resilient liquid milk sales across ANZ and the US. Management upgraded FY26 guidance, targeting mid-double-digit revenue growth and EBITDA margins of approximately 15.5%–16.0%.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au